医学
阿替唑单抗
三阴性乳腺癌
紫杉醇
转移性乳腺癌
肿瘤科
紫杉醇
内科学
人口
乳腺癌
成本效益
化疗
癌症
免疫疗法
彭布罗利珠单抗
风险分析(工程)
环境卫生
作者
Jiahao Li,Tiantian Zhang,Peiyao Lu,Jun Zhao,Lin Chen,Jie Jiang
出处
期刊:Immunotherapy
[Future Medicine]
日期:2020-07-01
卷期号:12 (10): 705-713
被引量:7
标识
DOI:10.2217/imt-2020-0036
摘要
Aim: To evaluate the cost-effectiveness of atezolizumab plus nab-paclitaxel (ANP) in the first-line treatment of metastatic triple-negative breast cancer (TNBC). Materials & methods: We developed a Markov model to evaluate the cost and effectiveness of ANP versus nab-paclitaxel in the first-line treatment of metastatic TNBC. Lifetime costs, life-years (LYs) and quality-adjusted LYs (QALYs) were estimated. Results: ANP provided an additional 0.16 QALYs (0.24 LYs) compared with nab-paclitaxel in intention-to-treat population. The corresponding incremental cost-effectiveness ratio was $786,131 per QALY gained. However, the incremental cost-effectiveness ratio decreased to $361,218 per QALY gained in the PD-L1 positive subgroup analysis. Conclusion: From the perspective of a US-payer, ANP is estimated not to be cost-effective in the first-line treatment of metastatic TNBC.
科研通智能强力驱动
Strongly Powered by AbleSci AI